Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis
The Correlation Study Between Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Guowen Shi, MD
- Phone Number: 86-13651932966
- Email: shigw228@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Recruiting
- Renji Hospital
-
Principal Investigator:
- Guowen Shi, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age : ≥ 18 years of age , ≤ 75 years old
- with intracranial artery stenosis in ischemic stroke
- the diagnosis of ischemic cerebrovascular disease are in line with the diagnostic criteria developed by the Chinese Medical Association Fourth National Cerebrovascular Disease Conference
- the patient admitted to hospital receive at least one examination like cranial MRI + DWI, MRA and TCD examination, clearly associated with intracranial arterial stenosis
- MRS score ≤ 3 points
Exclusion Criteria:
- vascular , cardiac , and unknown causes or other reasons lead to ischemic stroke
- associated with significant emotional disorders, cognitive impairment or other mental disorders can not be partners
- severe occlusion of Unilateral intracranial arteries ( over 90 % ) or bilateral stenosis more than 70%
- With extracranial artery stenosis, especially carotid and vertebral artery stenosis .
- patients with extracranial artery stenosis or patients previously done neck or intracranial artery balloon dilation , stent forming surgery or carotid endarterectomy
- Incomplete clinical data collection in patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: amlodipine
The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
|
The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
Atorvastatin 10 - 40mg / d ( statin therapy)
|
|
EXPERIMENTAL: ACEI / ARB
ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
|
aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
Atorvastatin 10 - 40mg / d ( statin therapy)
ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the incidence of stroke in a follow-up period
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
blood pressure during the compliance status in a follow-up
Time Frame: one year
|
one year
|
|
patients with blood pressure variability in a follow-up
Time Frame: one year
|
one year
|
|
Changes in intracranial arterial stenosis and stiffness before and after the follow-up
Time Frame: one year
|
one year
|
|
Other vascular events ( acute ischemic heart disease or vascular death )
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guowen Shi, MD, Renji Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pathological Conditions, Anatomical
- Stroke
- Ischemic Stroke
- Constriction, Pathologic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Aspirin
- Atorvastatin
- Clopidogrel
- Amlodipine
Other Study ID Numbers
Other Study ID Numbers
- RenJiH-20120804
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.